Overview of the Market:
Asia-Pacific Preclinical in-vivo imaging market has been estimated at USD 146.41 Million in 2018 and is projected to reach USD 225.27 Million by 2023, at a CAGR of 9.00% during the forecast period from 2018 to 2023. In-vivo imagers, also called as preclinical imaging systems, are imaging systems that look deep into the tissues of living subjects. The benefits of this type of system are that it gives the most complete picture of the biological effects of a treatment or disease progression and the animal is kept alive allowing future analysis on the same subject.
In Asia-Pacific region, factors like growing acceptance of preclinical imaging as a legitimate drug development tool and technological advancements in molecular imaging modalities are helping in the growth of the market. However, challenges associated with the application of radioisotopes, such as short half-life of PET radioisotopes restricts the demand for micro-PET systems in developing Asian countries.
Asia-Pacific market for Preclinical In-vivo Imaging is segmented based on Modality and Reagents. Based on modality, the Asia-Pacific preclinical imaging market is divided into seven major segments, namely, optical imaging, nuclear imaging, micro-MRI, micro-CT, micro-ultrasound, photoacoustic, and magnetic particle imaging systems. The preclinical optical imaging systems market includes bioluminescence/fluorescence imaging systems, standalone fluorescence imaging systems, optical + X-ray/optical + CT imaging systems. The preclinical nuclear imaging systems market comprises micro-PET systems (standalone PET, PET/CT, and PET/MRI), micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI), and tri-modality (PET/SPECT/CT) imaging systems. Bases on the reagents, the Asia-Pacific preclinical imaging market is divided into five segments, namely, optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents. The optical imaging reagents market is further sub-segmented as bioluminescent and fluorescent imaging reagents. Likewise, the nuclear imaging reagents market is divided as preclinical PET tracers and SPECT probes.
Geographical Analysis:
Geographically, Asia-Pacific market for Preclinical In-vivo Imaging is segmented into China, Japan, India, South Korea and Australia. Increased government funding for development of pharmaceutical industry and rising R&D activities by big pharma and biotech companies, are attracting the companies to invest in the countries of Asia-Pacific region.
key players in the market:
Aspect Imaging, Biospace Lab S.A., Bruker Corporation, LI-COR Biosciences, Mediso Ltd., MILabs B.V., MR Solutions Ltd, PerkinElmer, Inc., TriFoil Imaging, and FUJIFILM VisualSonics, Inc. are the key players operating in the Asia-Pacific preclinical imaging systems market.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Modality
5.1.1 Optical imaging
5.1.1.1 Bioluminescence/fluorescence imaging systems
5.1.1.2 Standalone fluorescence imaging systems
5.1.1.3 Optical + X-ray/optical + CT imaging systems
5.1.2 Nuclear imaging
5.1.2.1 Micro-PET systems (standalone PET, PET/CT, and PET/MRI)
5.1.2.2 Micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI)
5.1.2.3 Tri-modality (PET/SPECT/CT) imaging systems
5.1.3 Micro-MRI
5.1.4 Micro-CT
5.1.5 Micro-ultrasound
5.1.6 Photoacoustic
5.1.7 Magnetic particle imaging systems
5.2 By Reagent
5.2.1 Optical imaging reagents
5.2.1.1 Bioluminescent reagents
5.2.1.2 Fluorescent imaging reagents
5.2.2 Nuclear imaging reagents
5.2.2.1 Preclinical PET tracers
5.2.2.2 Preclinical SPECT probes
5.2.3 MRI contrast agents
5.2.4 Ultrasound contrast agents
5.2.5 CT contrast agents
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Aspect Imaging
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Biospace Lab S.A.
8.3 Bruker Corporation
8.4 LI-COR Biosciences
8.5 Mediso Ltd.
8.6 MILabs B.V.
8.7 MR Solutions Ltd
8.8 PerkinElmer
8.9 TriFoil Imaging
8.10 FUJIFILM VisualSonics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
